Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mohamad Sonbol

Hematology & Oncology Scottsdale, AZ Medical Doctor

NPI 1578904173 CMS profile 693270

13400 E Shea Blvd, Scottsdale, AZ 85259

Open in the dashboard

General payments

$10,639

8 records reported · program years 2021–2025

Research payments

$3,098

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,633,313 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Mohamad Sonbol of Scottsdale, AZ is reported in the CMS Open Payments database as having received $10,639 across 8 general payments and $3,098 in research payments paid to them. Separately, studies naming them as principal investigator received $1,633,313 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,077 3
2025 Research $3,098 1
2024 General $2,960 1
2022 General $3,590 3
2021 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohamad Sonbol
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Mohamad Sonbol were reported at $4,077. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Mohamad Sonbol Hematology & Oncology median Middle half National median
2019 $0 $529 $121–$2,516 $163
2020 $0 $339 $82–$2,213 $114
2021 $12 $263 $49–$1,965 $132
2022 $3,590 $416 $103–$2,395 $149
2023 $0 $542 $125–$2,646 $160
2024 $2,960 $692 $141–$3,008 $164
2025 $4,077 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $4,810 2 payments
  2. Novartis Pharmaceuticals Corporation $3,590 3 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $2,100 1 payment
  4. Tempus AI, Inc $127 1 payment
  5. Gilead Sciences, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $10,323 5 payments
  2. Food and Beverage $305 2 payments
  3. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Stivarga $2,100 1 payment
  2. XT CDX $127 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $3,098 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

300

Median for Hematology-Oncology: 604

Drug cost

$160,871

Median for Hematology-Oncology: $1,306,514

Branded share of claims

18.3%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xermelo Telotristat Etiprate Brand 12 $116,770
Creon Lipase/Protease/Amylase Brand 24 $40,518
Colestipol Hcl Generic 17 $1,021
Prochlorperazine Maleate Generic 79 $764
Dexamethasone Generic 44 $612
Olanzapine Generic 36 $480
Ondansetron Hcl Generic 58 $427
Loperamide Loperamide Hcl Brand 19 $141
Duloxetine Hcl Generic 11 $138

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 160 billing codes

Paid by Medicare

$2,536,307

Of which drugs: $2,397,580

Medicare patients

826

Average age 74

Services billed

111,843

385 women, 441 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Cancer 43%
Arthritis 41%
Chronic kidney disease 31%
Ischemic heart disease 28%
Diabetes 26%
Atrial fibrillation 25%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 58 12,780 $499,593
Injection, pembrolizumab, 1 mg J9271 Office 34 8,000 $354,622
Injection, nivolumab, 1 mg J9299 Office 20 8,520 $209,198
Injection, denosumab, 1 mg J0897 Office 15 1,740 $36,474
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg Q5115 Office 18 1,340 $35,403
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 Office 16 980 $34,463
Injection, bendamustine hcl (bendeka), 1 mg J9034 Office 11 2,100 $23,044
Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg Q5108 Office 14 192 $20,779
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 19 78 $10,902
Injection, bortezomib (velcade), 0.1 mg J9041 Office 19 875 $1,219

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

9 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record